The anti-tumor, oncolytic activity of RSV against androgen receptor-negative prostate tumors has additional clinical significance, since reduced or non-detectable androgen receptor expression has been observed in a small percent of metastatic neoplastic foci at distant organ sites from castrate resistant prostate cancer patients [32,33]. The gene discussed is AR; the disease is prostate carcinoma.